FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 595 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... April 9, 2024 How could proposed changes to data protection laws affect research? December 8, 2021 Blinatumomab Improves Survival in Children with Relapsed Leukemia April 1, 2021 Load more HOT NEWS For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms Combination of Azacitidine and Venetoclax in Previously Untreated AML
